Chapter 28: Coagulation Modifier Drugs – Anticoagulants & Antiplatelets

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

Welcome to the Deep Dive.

Today we're tackling something really critical drugs that literally balance life and death.

We're talking about clotting and bleeding.

Yeah, it's a tightrope walk, isn't it?

We're diving into coagulation modifier drugs, specifically pulling from Chapter 28 of Lilly's Pharmacology for Canadian Health Care Practice.

It's a chapter packed with high stakes information.

These aren't just any drugs.

Absolutely not.

The textbook is really clear on this.

Many of these, like heparin, warfarin, they're flagged as high alert drugs.

Why?

Because the potential for harm, for serious adverse reactions if they're ensued, it's just huge, among the highest actually.

Right.

So our mission today is clear.

Take this dense vital material and break it down for you, the listener, the student.

We want you to grasp the core concepts, the mechanisms, the safety points, the clinical must -knows without feeling totally swamped.

Exactly.

And, you know, before we even touch the drugs, the modifiers, we really have to get a handle on the body's own system, the coagulation process itself.

Okay.

Good point.

If you don't get the foundation, the rest won't make sense.

Precisely.

Understanding the normal process is step one.

All right.

Let's build that foundation.

There are some key terms that sometimes get mixed up.

Let's clarify.

Hemostasis versus coagulation.

What's the real difference?

Okay.

So, hemostasis is kind of the big picture.

It's any process that stops bleeding, could be you putting pressure on a cut, could be a stitch, or it could be the body's physiological response.

And coagulation.

Coagulation is more specific.

It's the physiological process, the cascade of events involving clotting factors and proteins that actually forms a blood clot.

It's a key part of hemostasis.

Got it.

And once that clot forms, it doesn't always stay put, right?

That's the thrombus versus embolus distinction.

Yes.

Crucial difference.

A thrombus is fixed.

It's a clot that's formed and is stuck to the wall of a blood vessel.

But if it breaks loose?

Then it becomes an embolus, a traveler.

And that's where the danger escalates dramatically.

That traveling clot can cause a DVT, a PE, a stroke.

Depends where it lodges.

Okay.

So to understand how we stop or start these processes with drugs, we need to understand the body's natural clot -making engine,

the coagulation cascade.

It sounds complicated.

It is intricate, but think of it like two different triggers setting off the same alarm system.

You've got the extrinsic pathway.

This one's kicked off by external damage, like a cut or trauma.

Tissue factor or thromboplastin gets released from the damaged cells.

Quick response?

Any other trigger.

That's the intrinsic pathway.

This one starts inside the blood vessel.

Usually when blood encounters something it shouldn't, like exposed collagen from damage to the vessel lining, factor 12 gets activated.

Different starting points, but they lead to the same place.

Exactly.

Both pathways, extrinsic and intrinsic, eventually merge.

Their common goal is to activate factor X, which ultimately leads to the creation of thrombin.

And thrombin's main job is converting fibrinogen into fibrin.

Fibrin.

That's the key structural component.

That's the stuff.

Fibrin is this insoluble protein that forms a mesh, kind of like a net, reinforcing the platelet plug and creating a stable, solid clot.

Okay, so the body builds the clot, but it also needs a way to clean up afterwards, right?

To break it down once healing starts.

Right.

And that's fibrinolysis, the body's own clot -dissolting system.

How does that work?

Well, there's an inactive protein called plasminogen circulating in the blood.

When needed, the body converts it into its active form, plasmin.

And plasmin is the clot buster.

Plasmin is the enzyme that literally chops up the fibrin mesh.

It breaks down the clot into smaller pieces that can be cleared away.

Think of it like enzymatic scissors.

Okay, makes sense.

Clot formation, clot breakdown.

This perfectly sets up the drug categories.

It does.

Because basically, all these drugs are designed to interfere with one part of this whole system.

You have anticoagulants, which prevent clots from forming by messing with the cascade factors.

Then antiplatelet drugs.

Those target the platelets themselves, stopping them from sticking together at the very beginning.

Then the heavy hitters.

The thrombolytic drugs.

These actually dissolve clots that have already formed.

The true clot busters.

And finally, the opposite.

Antifibrinolytic drugs.

These actually promote clot stability by preventing fibrinolysis, stopping the breakdown,

used when you need to stop excessive bleeding.

All right, let's drive into the first group.

Anticoagulants.

The preventers.

And a really crucial point right off the bat.

They prevent.

They don't dissolve.

That's absolutely fundamental to understand.

Anticoagulants will stop new clots or stop existing ones from getting bigger, but they have zero effect on a clot that's already there.

They can't segalize it.

Okay.

Let's start with the classic.

Heparin.

Unfractionated Heparin.

How does it work?

Heparin works by binding to a natural anticoagulant in our body called antithrombin the third, or AT3.

This binding dramatically boosts AT3's ability to shut down key clotting factors, primarily activated factor two, that's thrombin, and activated factor azaya, also factor all adds.

And because it hits multiple active factors, monitoring is key.

Which test?

That's the APT -activated partial thromboplastin time.

You need frequent checks to keep the patient in that therapeutic zone, usually aiming for 1 .5 to 2 .5 times whatever the control value is.

And administration.

Big safety point here.

Huge.

4 -fee or subcutaneous only.

Never ever give Heparin intramuscularly.

The risk of causing a massive painful hematoma, it's just too high.

It's a serious medication error.

Now contrast that with the low molecular weight Heparin's LMWHs, like inoxybarin.

What's different?

Well, they're derived from Heparin, but are smaller, more uniform molecules.

The structural difference makes them much more selective.

They predominantly target just factor azay, with less effect on thrombin.

And the big advantage of that selectivity?

Predictability.

Their effect is much more predictable dose to dose, patient to patient.

Which means, for the most part, you don't need routine APT monitoring.

This is huge for outpatient use and for bridge therapy, which we'll probably get into.

Okay.

Let's switch gears to the main oral anticoagulant, warfarin or coumadin.

Totally different mechanism, right?

Completely different.

Heparin works on factors already in the blood.

Warfarin works back in the liver at the factory.

It inhibits the synthesis of vitamin K.

And why is vitamin K important here?

Because several key clotting factors, specifically factors 2, 7, IX, and X, need vitamin K to be produced in their functional form by the liver.

So warfarin basically stops the liver from making new working versions of these factors.

So it doesn't affect the factors already floating around?

Not directly.

That's why it takes time to work.

Ah, okay.

And the monitoring test for warfarin?

That's the PTINR, prothrombin time, reported as the International Normalized Ratio.

We're usually aiming for an INR between 2 and 3 .5, depending on the reason for anticoagulation.

And you mentioned it takes time.

This is the critical lag period.

Yes.

Because warfarin only stops the production of new factors, you have to wait for the body to naturally clear out the already existing active factors.

This takes typically about 5 to 7 days for the full anticoagulant effect to be seen and the INR to become therapeutic.

Which highlights why that bridge therapy with heparin or LNWH is so vital when starting warfarin.

Absolutely essential.

You need that immediate protection from the heparinoid while the warfarin slowly takes effect.

You can't just start warfarin alone if you need rapid anticoagulation.

Okay, these are high alert drugs.

What about toxicity?

What are the antidotes?

Crucial knowledge.

For heparin overdose or toxicity, the antidote is protamine sulfate, given offy.

The dosing is specific.

About 1 mg of protamine neutralizes roughly 100 units of heparin.

And for warfarin?

For warfarin, it's vitamin K1, also known as fitonadione, can be given orally or parenterally depending on the urgency.

But there's a catch with giving vitamin K, isn't there?

There is.

While it effectively reverses warfarin, giving high doses of vitamin K can make the patient temporarily resistant to warfarin for up to a week afterwards.

This can make it really tricky to get them anticoagulated again if needed.

It's a balancing act.

And we have to mention a serious adverse effect of heparin, HIT, heparin -induced thrombocytopenia.

Yes, HIT.

Especially type 2 HIT.

It's this really dangerous paradoxical reaction where heparin exposure causes antibodies that activate platelets, leading to a drop in platelet count, but simultaneously causing widespread thrombosis or clotting.

Wow.

Okay, lower platelets but more clotting.

That sounds incredibly dangerous.

What do you do if type 2 HIT is suspected?

Immediate action.

Stop all heparin products immediately.

That includes flushes, coated catheters, everything.

And you must start a non -heparin anticoagulant like argotroban because the thrombotic risk is extremely high.

Okay.

Given the complexities of warfarin, the monitoring, the diet interactions, what about the newer oral anticoagulants, the NOACs or DOACs like the dabigatran or rivaroxaban?

Are they simpler?

They definitely offer advantages.

Dabigatran is a direct thrombin inhibitor, while rivaroxaban and others like apixaban are factor ZA inhibitors.

A key benefit is that for most patients, they don't require that routine coagulation monitoring like INR or APTT.

That sounds like a huge plus.

Any downsides?

Well, convenience sometimes comes with a trade -off.

While reversal agents are becoming available for some, historically a major concern was the lack of specific readily available antidotes for drugs like dabigatran or the older factor ZA inhibitor, fondaparanox.

Managing a major bleed could be more challenging, relying on supportive care, transfusions, maybe dialysis for dabigatran.

Right.

Okay, let's shift from the cascade inhibitors to the drugs acting earlier, the antiplatelets.

Section three.

Exactly.

If anticoagulants work on the fibrin formation part, antiplatelets work on the initial platelet plug formation.

They stop platelets from sticking together.

And the absolute classic here is aspirin, ASA.

How does it work on platelets?

Aspirin works by irreversibly inhibiting an enzyme called cyclooxygenase or COX.

In platelets, this blocks the formation of thromboxane A2 or TXA2.

And TXA2 is usually proplatelet.

Very much so.

TXA2 causes platelets to aggregate and also causes vasoconstriction.

So by blocking its formation, aspirin makes platelets less sticky.

And because that inhibition is irreversible, it lasts for the entire lifespan of that platelet, which is about seven days.

One dose has a long effect.

Important safety note with aspirin, though.

Yes, definitely.

Aspirin should not be given to children or teenagers with flu -like symptoms or viral illnesses due to the risk of Rays syndrome, a potentially fatal condition affecting the brain and liver.

Okay.

What about other antiplatelets like clopidogrel?

Clopidogrel belongs to a class called ADP inhibitors.

It works differently than aspirin.

It essentially alters the platelet membrane by blocking the ADP receptor, which prevents the activation of another key receptor called GPI -BIA.

So it stops the signal for aggregation.

Pretty much.

It stops the platelet from getting the message to activate and stick.

Clopidogrel is often used together with aspirin that's called dual antiplatelet therapy, or DAPT, especially after things like coronary stents.

And there are drugs that target that GPI -BIA receptor directly.

Yes.

The GPI -BIA inhibitors like eptifibatide or tyrophiban, these are potent, IV -only drugs.

They directly block that final common pathway receptor needed for platelets to link together.

You typically see them used in high -risk situations, like during angioplasty or for unstable angina, to prevent clot formation right then and there.

And the main risk across all these antiplatelet agents.

Bleeding again.

That's the common theme.

Contraindications generally include active bleeding, known bleeding disorders, severe

thrombocytopenia, recent hemorrhagic stroke, things like that.

You have to weigh the benefit against the bleeding risk.

OK, let's move to the other end of the spectrum now.

Section four, thrombolytics, the clot busters.

These are the ones that do dissolve existing clots.

Yes, these are the heavy artillery.

Drugs like alteplase, which is recombinant tissue plasminogen activator, or TPA.

They are used in emergencies like acute MI, ischemic stroke, or massive pulmonary embolism.

And their mechanism is basically turbocharging the body's own fibrinolysis.

Exactly.

Alteplase mimics the body's natural TPA.

It binds to fibrin within the thrombus and converts the trapped plasminogen directly into plasmin right at the site of the clot.

Plasmin then gets to work, dissolving the fibrin mesh.

You mentioned at the site of the clot.

Is that an important distinction?

It is, especially with the newer thrombolytics.

They are more fibrin -specific.

Older agents were less specific and activated plasminogen throughout the bloodstream, leading to a higher risk of systemic bleeding.

These newer ones focus their action more where the fibrin clot actually is, which theoretically reduces that systemic risk, though bleeding is still the major concern.

Okay, so those are the busters.

Now, what about the drugs that do the opposite promote clotting?

The antifibrinolytics or hemostatics?

Right.

These are used when the problem isn't clotting too much, but bleeding too much.

Their job is to prevent the breakdown of fibrin, essentially stabilizing the clot that has formed.

What are some examples?

There are synthetic ones like tranexamic acid and aminocoproic acid.

And there's also desmopressin, which is interesting.

How does desmopressin work here?

It's also used for diabetes and sympathies, right?

It is, but it has effects on clotting too.

Desmopressin increases the levels of on Willebrand factor and factor VIII circulating in the blood.

Both of these are important for platelet adhesion and clot formation.

So it helps boost the clotting process, useful in certain bleeding disorders like von Willebrand's disease, or mild hemophilia A, or sometimes before surgery.

Fascinating how one drug can have different uses.

Okay, this brings us to the crunch time.

Section 5, clinical relevance and nursing considerations.

What does all this mean for practice?

This is where the knowledge becomes action, and safety is paramount.

Assessment is key.

Constantly.

You're always looking for signs of bleeding obvious ones, like nosebleeds, epistaxis,

Blood in stool, Melina.

But also subtle signs like petechiae, unusual bruising, gum bleeding.

And monitoring those labs we talked about.

Absolutely.

Know which drug needs which test.

INR for warfarin reflects liver synthesis.

APTT for unfractionated heparin reflects circulating factor inhibition.

Get those timings and targets right.

Let's talk about administration safety, specifically for the injectables like heparin and LMWHs.

Technique matters.

Hugely.

Subcutaneous injection, usually in the abdomen, is preferred, but you must stay at least 5 cm or 2 inches away from the umbilicus.

Rotate sites.

And the absolute golden rule, do not aspirate before injecting and do not massage the site afterwards.

Why not?

Both actions can cause trauma to the tissue and increase the risk of forming a painful hematoma or excessive bruising at the site.

Just inject, withdraw the needle, and apply gentle pressure if needed, but no rubbing.

Critical point.

And let's hammer home that deadly error again.

Yes.

You never give unfractionated heparin and a low -molecular -weight heparin like anoxaparin concurrently to the same patient.

The combined anticoagulant effect is dangerously high, massively increasing the risk of major hemorrhage.

Check, double -check, triple -check medication orders.

Okay.

And regarding warfarin management, let's reinforce that bridge therapy concept one more time for clarity.

Right.

Because warfarin takes those 5 -7 days to reach full effect, if a patient needs immediate anticoagulation, like for a DVT or PE, you start them on both warfarin and rapid -acting agent like heparin or LMWH.

You continue the heparin or LMWH until the INR, driven by the warfarin, has been stable within the therapeutic range, usually 2 -3 .5, for at least 24 hours, often longer depending on protocol.

Then, you stop the injectable.

The bridge covers the gap.

Makes sense.

You also mentioned a specific storage requirement for Dabig and Tran earlier.

Yes.

That's a really practical point for patient education.

Dabig and Tran are very sensitive to moisture.

They must be stored in their original manufacturer bottle, which contains a desiccant, and the cap must be kept tightly closed.

Don't put them in pill organizers.

Once the bottle is open, the medication is only considered stable for about 4 months.

Using it beyond that, or if stored improperly, it might not be potent enough.

Good detail.

Lastly, patient education around warfarin and diet.

What's the real advice on vitamin K foods like leafy greens?

The key isn't avoidance, it's consistency.

Patients on warfarin need to maintain a steady, consistent intake of foods containing vitamin K.

Suddenly, eating tons of spinach salads one week and none the next will throw their INR away off.

So eat normally, but keep the intake stable day -to -day, week -to -week.

And other lifestyle advice.

Definitely advise them to avoid activities with a high risk of injury.

Use an electric razor instead of a straight razor.

Use a soft bristle toothbrush.

And crucially, they should wear a medical alert bracelet or carry a card stating they are on an anticoagulant.

That's vital in an emergency.

Wow.

We have certainly covered a lot of ground.

The Preventers, anticoagulants like heparin, warfarin, LMWHs, NOACs.

The aggregation blockers, antiplatelets like aspirin and clopidogrel.

The powerful clot busters, thrombolytics like alteplaser and the clot promoters, antifibrinolytics like desmopressin and tranexamic acid, plus all the crucial monitoring, antidotes and safety measures.

It's a complex area, but absolutely vital.

And thinking about warfarin specifically, you know, that constant need for dietary vigilance, the INR checks, it really highlights a unique challenge in chronic medication management.

It leads me to a final thought for you, our listeners, to ponder.

Okay.

Given that warfarin success is so directly tied to a patient's consistent dietary choices regarding vitamin K, how does this ongoing daily requirement potentially shape the long -term relationship between patient adherence, their nutritional habits, and the ultimate success or failure of their therapy compared to drugs that don't demand such constant lifestyle integration?

That's a really interesting question.

How does that deep entanglement of diet and drug affect adherence and outcomes long -term?

Something definitely worth thinking about as you integrate all this information.

Indeed.

Well, thank you for joining us on this deep dive into the complex world of coagulation modifiers.

We really hope this breakdown helps you get a solid grasp on this challenging but essential subject matter.

Keep studying.

You'll get it.

Good luck.

From all of us here in the Last Minute Lecture family, thanks for tuning in.

We truly appreciate you being here, and we'll catch you on the next deep dive.